Explore

Rapid Read Rapid Read
NHS GP Warns Omeprazole Patients of Long-Term Risks and Urges Regular Check-Ups

NHS GP Warns Omeprazole Patients of Long-Term Risks and Urges Regular Check-Ups

Dr. Punam Krishan, an NHS GP and BBC Morning Live's resident doctor, has issued a warning to patients using proton pump inhibitors (PPIs) like omeprazole for conditions such as heartburn, acid reflux, and indigestion. She emphasized the importance of regular medical reviews for those on long-term PPI treatment to avoid potential health risks. Dr. Krishan highlighted that while PPIs are effective in managing acid reflux by reducing stomach acid production, prolonged use can lead to deficiencies in magnesium and vitamin B12, and increase the risk of gut infections like Clostridioides difficile. She advised patients to consult their doctors if they experience persistent symptoms or alarming signs such as difficulty swallowing or bloody vomit. Regular check-ups are crucial for those prescribed omeprazole for over a year to minimize long-term side effects.
Trendline Trendline
CVS Caremark Utilizes Technology to Expedite Prior Authorization, Enhancing Patient Access

CVS Caremark Utilizes Technology to Expedite Prior Authorization, Enhancing Patient Access

CVS Caremark Utilizes Technology to Expedite Prior Authorization, Enhancing Patient Access
Trendline Trendline
FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability
Rapid Read Rapid Read
AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

Scientists from the Institute of Cancer Research in London and the RCSI University of Medicine and Health Sciences in Dublin have developed an AI tool called PhenMap. This tool is designed to identify colorectal cancer (CRC) patients who are most likely to benefit from the drug bevacizumab, which has recently been approved for NHS use in treating metastatic CRC. The AI analyzes genetic data and other clinical information to score patients based on their likelihood of benefiting from the drug, which is known to cause serious side effects in some patients. The research, published in Scientific Reports, aims to improve treatment outcomes and reduce unnecessary side effects by targeting the drug to patients who will benefit the most.
Rapid Read Rapid Read
FDA Rejects Replimune's Melanoma Therapy, Impacting Patients and Company

FDA Rejects Replimune's Melanoma Therapy, Impacting Patients and Company

Replimune's advanced melanoma treatment, RP1, has been rejected by the FDA for the second time. The therapy, which combines RP1 with Bristol Myers Squibb's Opdivo, was intended for patients with advanced melanoma who have not responded to anti-PD-1 treatments. The FDA's decision was based on concerns about the trial data, including the inability to distinguish RP1's effects from Opdivo and issues with the patient population size. Replimune has criticized the FDA for inconsistent communication and a fragmented regulatory process, claiming the decision contradicts expert opinions and patient needs. The rejection has led to significant financial and operational impacts for Replimune, including job cuts and reduced manufacturing operations.
Trendline Trendline
Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent
Rapid Read Rapid Read
United States Pharmacopeia Expands Vulnerable Drug List Amid Supply Chain Concerns

United States Pharmacopeia Expands Vulnerable Drug List Amid Supply Chain Concerns

The United States Pharmacopeia (USP) has updated its list of drugs vulnerable to supply chain disruptions, adding medications such as Tamiflu and Trulicity. This update follows an expanded risk assessment that now includes key starting materials (KSMs), which are essential for producing active pharmaceutical ingredients. The USP's analysis revealed that 48 of the 100 vulnerable drugs rely on KSMs sourced from a single country, highlighting potential supply chain risks. Notably, 41% of KSMs for U.S.-approved active pharmaceutical ingredients are sourced solely from China, while 16% come from India. The USP's findings indicate that despite stable finished product availability, these drugs have a single upstream point of failure, making them susceptible to supply disruptions.
Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul
Trendline Trendline
FDA's CRL Transparency Policy Enhances Biopharma Accountability

FDA's CRL Transparency Policy Enhances Biopharma Accountability

FDA's CRL Transparency Policy Enhances Biopharma Accountability
Rapid Read Rapid Read
Trump Administration Considers Houman Hemmati for Top FDA Vaccine Post Amid Scrutiny

Trump Administration Considers Houman Hemmati for Top FDA Vaccine Post Amid Scrutiny

The Trump administration is evaluating Houman Hemmati, an ophthalmologist and frequent Fox News guest, for a leading role at the Food and Drug Administration (FDA) as the top regulator of vaccines and treatments for complex diseases. This consideration comes as Vinay Prasad, the current holder of the position, is set to leave at the end of April after a contentious tenure marked by controversial drug approval decisions. FDA Commissioner Marty Makary reportedly supports Hemmati's candidacy, although no final decision has been made. Hemmati's potential appointment is occurring during a period of increased scrutiny from the White House on FDA operations, which has unsettled the pharmaceutical industry that depends on the agency's consistent regulatory framework.
Rapid Read Rapid Read
GOSH Project Shows Switching Children from Liquid to Tablet Medication Saves Money and Improves Quality of Life

GOSH Project Shows Switching Children from Liquid to Tablet Medication Saves Money and Improves Quality of Life

A project conducted by Great Ormond Street Hospital (GOSH) has demonstrated that switching children with congenital hyperinsulinism (CHI) from liquid diazoxide to tablet form can significantly improve their quality of life and save money. The study involved 19 children aged seven years or older, who successfully transitioned to tablets without negative effects on their blood glucose levels. The switch resulted in substantial cost savings, with tablet formulations costing significantly less than liquid alternatives. GOSH's endocrinology team is now exploring the possibility of supporting younger patients in making the switch, as part of the hospital's 'GOSH green plan 2024 to 2027'.
Trendline Trendline
Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny